Weather AlertWe are monitoring the weather's impact on our services. If you are experiencing a medical emergency, call 911 or go to the nearest emergency department. Mass General Brigham's emergency departments remain open. For real-time updates and service changes, please check our Alerts page.View Alerts page
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
A Phase I Study to evaluate the safety and maximum tolerated dose of Momelotinib During and Following Hematopoietic Cell Transplantation for Patients With Myelofibrosis
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
A randomized, placebo-controlled phase 2 study of IDH1 inhibition using ivosidenib as maintenance therapy for IDH1-mutant acute myeloid leukemia following allogeneic stem cell transplantation
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
An Open Label Phase I Study of Ziftomenib as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation
Phase 2 study of Ruxolitinib-based primary treatment for acute GVHD